CD274 and neoplasm: Hence, anti-PD-1/PD-L1 inhibitors cannot exert anti-tumour effects until they activate the immune system and consequently generate a series of specific reactions that combat tumour cells; thus, in clinical practice, it takes longer for their effects to be seen49,50.